Performance of 30 commercial SARS-CoV-2 serology assays in testing symptomatic COVID-19 patients.
Eur J Clin Microbiol Infect Dis
; 40(10): 2235-2241, 2021 Oct.
Article
in English
| MEDLINE | ID: covidwho-1156953
ABSTRACT
We report evaluation of 30 assays' (17 rapid tests (RDTs) and 13 automated/manual ELISA/CLIA assay (IAs)) clinical performances with 2594 sera collected from symptomatic patients with positive SARS-CoV-2 rRT-PCR on a respiratory sample, and 1996 pre-epidemic serum samples expected to be negative. Only 4 RDT and 3 IAs fitted both specificity (> 98%) and sensitivity (> 90%) criteria according to French recommendations. Serology may offer valuable information during COVID-19 pandemic, but inconsistent performances observed among the 30 commercial assays evaluated, which underlines the importance of independent evaluation before clinical implementation.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Immunoassay
/
COVID-19 Serological Testing
/
SARS-CoV-2
/
COVID-19
/
Antibodies, Viral
Type of study:
Diagnostic study
/
Experimental Studies
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Eur J Clin Microbiol Infect Dis
Journal subject:
Communicable Diseases
/
Microbiology
Year:
2021
Document Type:
Article
Affiliation country:
S10096-021-04232-3
Similar
MEDLINE
...
LILACS
LIS